Habib Bennaceur: Novo Nordisk Completed its Acquisition of Zaltenibart from Omeros Corporation
Habib Bennaceur, SVP Rare Disease Unit at Novo Nordisk, shared on LinkedIn:
”I am pleased to share that Novo Nordisk completed its acquisition of zaltenibart from Omeros Corporation strengthening our commitment to address unmet needs in rare blood and kidney disorders.
This addition expands our portfolio in haematology and renal as we continue working to serve more people and communities living with rare diseases.
Zaltenibart is an investigational antibody designed to precisely target MASP-3 in the complement system, representing a novel mechanism of action for our haemato-renal portfolio.
Early clinical data in paroxysmal nocturnal haemoglobinuria (PNH) is encouraging, and we look forward to advancing zaltenibart’s development and exploring its potential to provide new treatment options as we drive lasting change in rare disease.”
Stay updated with Hemostasis Today.
-
Mar 2, 2026, 17:22Hematologists and Oncologists Recognize Their Role in Specialized VA Care Despite Ongoing Knowledge Gaps – JTH
-
Mar 2, 2026, 17:04Fernando Corrales-Medina: An Evidence-Based Platform Promoting Early Recognition and Evaluation of VWD
-
Mar 2, 2026, 16:56Mbunya S. Misiani: Changing the Narrative on Bleeding Disorders Across Africa
-
Mar 2, 2026, 16:51Ofoke Chiamaka: Rehabilitation Is Not Just Muscle Training, It Is Brain Retraining
-
Mar 2, 2026, 16:41Paul Bolaji: Beyond Acute Stroke Care – Independent Integrated Living After Stroke
-
Mar 2, 2026, 16:37Gianluca Franceschini: Precision Medicine Is Only Truly Effective If It Is Inclusive
-
Mar 2, 2026, 16:34Maha Othman: Calling a Guest Editor for Current Opinion in Hematology
-
Mar 2, 2026, 16:30Tareq Abadl: Erythropoiesis – The Cellular Engineering Behind Oxygen Delivery
-
Mar 2, 2026, 16:28Tagreed Alkaltham: Blood Management in Times of Crisis